New Treatment May Nearly Eliminate Dangerous Lp(a) Levels

In a major breakthrough presented at the American College of Cardiology (ACC) annual meeting, researchers unveiled a novel drug—lepodisiran—that has shown impressive results in reducing lipoprotein(a) or Lp(a) levels by nearly 100% in clinical trials 

Since elevated Lp(a) is a strong genetic risk factor for heart disease and stroke that’s resistant to lifestyle change, this development has the potential to reshape how we approach cardiovascular prevention.

Involving over 300 participants across 10 countries, the trial demonstrated sustained reduction in Lp(a) following a single injection at six months, with continued effect one year later. While safety data is favorable, larger phase 3 trials are underway to determine if lowering Lp(a) actually reduces cardiovascular events like heart attacks and strokes.



If validated in further studies, lepodisiran could fill a critical gap in current cardiovascular treatment—especially for individuals with genetically elevated Lp(a) who otherwise have few options. 

Why This Matters

Unmet Need: Lp(a) affects over 1.4 billion people globally and isn’t responsive to diet or existing lipid drugs.

Precision Therapy: Offers targeted intervention for high-risk individuals.

Potential Game-Changer: Could redefine cardiovascular risk reduction and preventative strategies.

To know more visit: https://www.cardiology.scientexconference.com/

Comments

Post a Comment

Popular posts from this blog

Image
  Ventricular Assist Device – Miniature The treatment of individuals with severe heart failure has been transformed by the development of a ventricular assist device (VAD). When a donor heart cannot be identified, the VAD, which was initially designed as a bridge to transplantation , has been proved to extend life and improve quality of life. Older models needed patients to ambulate with hefty , huge external batteries and control devices and required the implantation of a big pump. Yet in the upcoming years, a number of ground-breaking advancements in device size , battery life, and even wireless charging technologies may render these devices physically undetectable and possibly reduce patient vulnerability to infections. The rates of haemolysis, thrombosis, and secondary aortic valve insufficiency have also been constrained by numerous mechanical improvements and newer operating paradigms. Cardiac Decellularization and Engineered Heart Tissue Promising new direction...
Read more
Image
Myocardial infarction events involving morality, incredibly high temperatures, and minute particles.  Myocardial infarction (MI) morbidity has been connected to extreme temperature events (ETEs), such as heat wave and cold spell, but their effects on MI mortality are less well understood. Although ambient fine particulate matter (PM2.5) and severe temperatures may work in concert to increase cardiovascular mortality , it is still unclear whether or how ETEs and PM2.5 interact to cause MI deaths.METHODS: To examine the relationship between exposure to ETEs and PM2.5 and MI mortality and assess their interacting effects, a time-stratified case-crossover study of 202 678 MI deaths in Jiangsu province, China, from 2015 to 2020 was conducted. Twelve ETE definitions were created using a variety of temperature thresholds and durations based on the perceived ambient temperature. In order to estimate daily ETEs and PM2.5exposures , values were taken from validated grid datasets at reside...
Read more

New Drug Nearly Eradicates “Stealth” Cholesterol (Lp(a)) – A Game‑Changer in Heart Disease Prevention

Image
A recent clinical trial reported in the New England Journal of Medicine and showcased at the American College of Cardiology revealed that lepodisiran—an experimental RNA-targeting drug—can reduce lipoprotein(a) [Lp(a)] by nearly 100% after a single dose, with sustained effects over a year 🔍 What You Need to Know Lp(a) is a genetically determined, stealth cholesterol that significantly raises the risk of heart attacks and strokes yet is not addressed by diet or standard statins. The Phase 2 trial, involving 320 participants across 10 countries, showed almost total Lp(a) suppression at 6 months, maintained at 1 year. Reported side effects were mild, primarily limited to injection-site reactions. No serious safety issues were found.                      🌍 Why This Matters This breakthrough could pave the way for targeted Lp(a) therapies—potentially reducing cardiovascular risk in over 1.4 billion people globally with elevated levels....
Read more